特布他林联合羧甲司坦片治疗慢性阻塞性肺疾病的疗效及对血清MMP-9、MMP-12、TIMP-1的影响

目的:研究特布他林联合羧甲司坦片治疗慢性阻塞性肺疾病的疗效及对血清基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶-12(MMP-12)、组织型金属蛋白酶抑制物(TIMP-1)水平的影响。方法:选取2015年3月至2018年2月我院收治的170例COPD患者,根据随机数字法分为观察组(87例)和对照组(83例)。对照组使用特布他林,观察组联合使用羧甲司坦。比较两组患者的临床疗效,治疗前后血清MMP-9、MMP-12、TIMP-1水平,肺功能指标,炎性因子水平的变化及不良反应的发生情况。结果:治疗后,观察组临床总有效率显著高于对照组(P<0.05),血清MMP-9、MMP-12、TIMP-1水平显著低于对照组(P<0.05),最大呼气流速(PEF)、1秒用力呼气容积(FEV1)、用力肺活量(FVC)及FEV1/FVC显著高于对照组(P<0.05),血清肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)、中性粒细胞弹性蛋白酶(NE)水平均显著低于对照组(P<0.05)。观察组和对照组不良反应的发生率比较无显著差异(P>0.05)。结论:特布他林联合羧甲司坦片治疗COPD的临床疗效显著优于单用特布他林,且安全性更高,可能与其能有效降低血清MMP-9、MMP-12、TIMP-1水平有关。

Efficacy of Terbutaline Combined with Carboxymethacetin Tablets in the Treatment of Chronic Obstructive Pulmonary Disease and Its Effect on the Serum MMP-9, MMP-12 and TIMP-1

Objective: To study the efficacy of terbutaline combined with carboxymethine tablets in the treatment of chronic obstructive pulmonary disease and serum levels of matrix metalloproteinase-9(MMP-9), matrix metalloproteinase-12(MMP-12), tissue effect of type metalloproteinase inhibitor(TIMP-1). Methods: A total of 170 patients with COPD admitted in our hospital from March 2015 to February 2018 were enrolled, they were diveided into the observation group(87 patients) and the control group(83 patients) according to random number method. Terbutaline was used in the control group, and observation group combined with carboxymethylstatin. The clinical efficacy, serum levels of MMP-9, MMP-12 and TIMP-1 before and after treatment, lung function indicators, changes of inflammatory factors and occurrence of adverse reactions were compared between the two groups. Results: After treatment, the total clinical effective rate of the observation group was significantly higher than that of the control group(P<0.05). the serum MMP-9, MMP-12 and TIMP-1 levels in the observation group were significantly lower than the control group(P<0.05). the observation group with the ratios of PEF, FEV1, FVC and FEV1/FVC were significantly higher than those of the control group(P<0.05). The Serum of levels TNF-α, IL-8 and NE in the observation group were significantly lower than those in the control group(P<0.05). There was no significant difference in the incidence of adverse reaction between the observation group and the control group(P>0.05). Conclusion: The clinical efficacy of terbutaline combined with carboxymethylsteine tablets in the treatment of COPD is significantly better than that of terbutaline alone, and its safety is higher, which may be related to its effective reduction of serum levels of MMP-9, MMP-12 and TIMP-1.